MIR133A1

Summary

MIR133A1 (microRNA 133a-1, HGNC:31517) is a microRNA gene on chromosome 18q11.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406922 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31517
Approved symbol	MIR133A1
Name	microRNA 133a-1
Location	18q11.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-133a-1
Ensembl gene	ENSG00000283927
Ensembl biotype	miRNA
OMIM	610254
Entrez	406922
RNAcentral	URS00005EB596 — miRNA, 88 nt, 35 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385052

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385052 — 1 exons

Exon	Start	End
ENSE00001437067	21825698	21825785

Expression profiles

Bgee: expression breadth broad, 21 present calls, max score 73.82.

Top tissues by expression

21 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
anterior cingulate cortex	UBERON:0009835	73.82	gold quality
body of stomach	UBERON:0001161	67.32	gold quality
heart left ventricle	UBERON:0002084	66.58	gold quality
left ovary	UBERON:0002119	65.54	gold quality
ascending aorta	UBERON:0001496	65.02	gold quality
subcutaneous adipose tissue	UBERON:0002190	64.62	gold quality
apex of heart	UBERON:0002098	64.11	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	63.94	gold quality
right frontal lobe	UBERON:0002810	63.58	gold quality
skin of leg	UBERON:0001511	62.61	gold quality
lower esophagus muscularis layer	UBERON:0035833	61.72	gold quality
skin of abdomen	UBERON:0001416	61.41	gold quality
endocervix	UBERON:0000458	59.81	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	59.09	gold quality
cerebellar hemisphere	UBERON:0002245	58.65	gold quality
left lobe of thyroid gland	UBERON:0001120	55.48	gold quality
thyroid gland	UBERON:0002046	55.25	gold quality
spleen	UBERON:0002106	54.74	gold quality
prostate gland	UBERON:0002367	53.58	gold quality
right atrium auricular region	UBERON:0006631	52.90	gold quality
right testis	UBERON:0004534	46.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-133a showed dysregulation in myocardial infarction or fetal hearts when compared to healthy adults. (PMID:20075508)
• Prolonged high-glucose exposure down-regulates PTB levels and insulin biosynthesis rates in human islets by increasing miR-133a levels. (PMID:20520763)
• Data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in bladder cancer (BC). (PMID:20843712)
• Downregulation of miR-133a is associated with esophageal squamous cell carcinoma. (PMID:21351259)
• miR-133a down-regulation is associated with bladder cancer. (PMID:21396852)
• elevated levels of circulating miR-133a in patients with cardiovascular diseases originate mainly from the injured myocardium. (PMID:21642241)
• Results describe the profile of miR-1, miR-133a, miR-133b and miR-206 in human muscle cells isolated during different stages of fetal development. (PMID:21645416)
• The functional significance of miR-133a in cancer cell lines derived from lung squamous cell carcinoma (SCC) and the identification of miR-133a-regulated novel cancer networks in lung-SCC, are reported. (PMID:22089643)
• this analysis data of novel tumor-suppressive miR-133a-mediated cancer pathways could provide new insights into the potential mechanisms of HNSCC oncogenesis. (PMID:22266319)
• Aberrant expression and functional significance ofthe miR-1/miR-133a and miR-206/miR-133b clusters in human cancers. (PMID:22308266)
• Levels of ARPC5 expression were significantly higher in invasive cancer cells and gene expression was directly regulated by miR-133a. (PMID:22378351)
• findings showed miR133a and miR-133b are expressed at in 2 hormone-insensitive prostate cancer cell lines, PC3 and DU145; ectopic expression of miR-133 inhibited cell proliferation, migration and invasion in these cells; first evidence that miR-133 may target EGFR (PMID:22407299)
• Data suggest that microRNA/mRNA pairs in hsa-miR-140-3p/RAD51AP1/, hsa-miR-145/E2F3, hsa-miR-139-5p/TOP2A, and hsa-miR-133a/GCLC were correlated with ovarian tumorigenesis. (PMID:22452920)
• Studies indicate that the plasma miR-133 and miR-328 are increased 11- to 16-fold in patients with acute myocardial Infarction. (PMID:22713968)
• Data suggest that up-regulation of miR-133a in chorion/chorionic villi is involved in pathogenesis of recurrent spontaneous abortion; up-regulation of miR-133a and binding to 3-prime-UTR of HLA-G (MHC class I G) gene down-regulates HLA-G expression. (PMID:22877943)
• Human bone marrow-derived mesenchymal stem cells transfected with microRNA-133a (miR-133a), which targets EGFR, were observed to express cardiac-specific markers. (PMID:23069713)
• miR-133a appears to have a direct regulatory effect on expression of VKORC1 in humans. (PMID:23154637)
• miR-133a serum levels were increased in patients with chronic liver disease and indicated the presence and progression of liver cirrhosis (PMID:23183523)
• MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. (PMID:23206218)
• Several miRNAs differentially expressed between umbrella and basal-intermediate cells (miR-133a, miR-139-3p, miR-142-3p, miR-199b-5p, and miR-221). (PMID:23410519)
• findings showed miR-133a was frequently downregulated in colorectal cancer tissues and colon cancer lines; restoration of miR-133a in colon cancer cells resulted in G0-G1 cell-cycle arrest and suppressed cancer cell growth; miR-133a serves as a potential tumor suppressor upstream of p53 in colorectal cancer and may sensitize cells to therapeutics (PMID:23723074)
• the anti-tumor effect of miR-133a was probably due to targeting and repressing of Bcl-xL and Mcl-1 expression. (PMID:23756231)
• Reduced miR133a expression is associated with lung cancer. (PMID:23783274)
• Data show that miR-133a can target the 3’ untranslated region (3’UTR) of LIM and SH3 protein 1 (LASP1) mRNA and suppress the expression of LASP1. (PMID:23968734)
• Overexpression of miR-133a-1 increases Caspase-1 p10 and IL-1beta p17 cleavage, concurrently suppressing mitochondrial uncoupling protein 2 (UCP2). (PMID:23988448)
• The results showed that circulating miR-133a level was significantly increased in acute myocardial infarction patients in time-dependent manner. (PMID:24053180)
• Rescue experiments showed that ectopic expression of IGF1R significantly promoted the proliferation of ovarian cancer cells stably overexpressing miR-133a (PMID:24127040)
• miR-499 and miR-133a may have a role in myocardial infarct and be possible diagnostic biomarkers [meta-analysis] (PMID:24533109)
• findings indicate that sequence variants of miR-1-1, miR-1-2, miR-133a-1 and miR-133a-2 are not a cause of LQTS in this cohort (PMID:24809446)
• the tumor suppressor role of miR-133a in lung cancer (PMID:24816813)
• Circulating level of miR-133 is associated with acute myocardial infarction. (PMID:24885383)
• This review identified and summarized the results of studies of miR-133 with emphasis on its function in human diseases in muscle and cancer.[Review] (PMID:24975488)
• miR-133a was downregulated in colorectal cancer tissues, but its higher expression correlated with adverse clinical characteristics and poor prognosis. (PMID:25104873)
• Suggest circulating miR-1, miR-133a, and miR-206 as potential biomarkers of muscle damage or adaptation to exercise. (PMID:25146754)
• The downregulation of miR-133a may play an important role in the progression of colorectal cancer and can be used as an independent factor to determine CRC prognosis. (PMID:25170220)
• miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. (PMID:25198665)
• Study suggests a potential use of miR-21 and miR-133a as sensitive and plasma biomarkers for postmenopausal osteoporosis. (PMID:25231354)
• Combined expression of miR-133a and miR-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma. (PMID:25280517)
• TAGLN2 modulates hypoxia-induced apoptosis via caspase-8 apoptotic pathway. Taken together, our data demonstrated the roles of miR-133a in hypoxia-induced apoptotic and implicate its potential in cardiac dysfunctions therapy. (PMID:25421410)
• Downregulation of miR-133a is associated with arteriosclerosis obliterans of the Lower Extremities. (PMID:25445891)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir133a-1	ENSDARG00000104548
mus_musculus	Mir133a-1	ENSMUSG00000065399
rattus_norvegicus	Mir3582	ENSRNOG00000035651

Paralogs (2): MIR133B (ENSG00000199080), MIR133A2 (ENSG00000284508)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.